Skip to main content

Table 1 Patient characteristics of the control group and each fibrinogen concentrate dose subgroup

From: Fibrinogen levels in trauma patients during the first seven days after fibrinogen concentrate therapy: a retrospective study

  Control group 1–4 g FC 5–9 g FC ≥10 g FC P-valuea
(n = 193) (n = 97) (n = 93) (n = 52)
Age, years 50 (37–65) 40 (22–56) 41 (26.5–53) 43.5 (28–53.75) <0.0001
Male, n (%) 153 (79.3) 69 (71.1) 75 (80.6) 39 (75.0) 0.3513
ISS 22 (17–27.5) 29 (25–40) 34 (23–45) 41.5 (33.25–50) <0.0001
Mortality, n (%) 12 (6.2) 4 (4.1) 5 (5.4) 8 (15.4) 0.0533
Massive transfusion, n (%) 1 (0.5) 8 (8.2) 26 (28.0) 45 (86.5) <0.0001
FC, g 3 (2–4) 6 (6–8) 12 (10.25–15.75) <0.0001
RBC      
 units (total) 0 (0–0) 3 (2–6) 7 (5–10) 15 (11.35–20.75) <0.0001
n (%) 25 (13.0) 74 (76.3) 87 (93.5) 52 (100) <0.0001
 unitsb 3 (2–4.5) 4.5 (3–7) 7.0 (5–10) 15.0 (11.25–20.75) <0.0001
PCC      
 IU (total) 0 (0–0) 0 (0–0) 300 (0–1800) 3600 (1800–5400) <0.0001
n (%) 5 (2.6) 22 (22.7) 46 (49.5) 50 (96.2) <0.0001
 IUb 1800 (1200–4500) 1200 (1150–1800) 1800 (1425–2400) 3600 (1800–5425) <0.0001
Platelet concentrate      
 units (total) 0 (0–0) 0 (0–0) 1 (0–2) <0.0001
n (%) 1 (1.0) 17 (18.2) 28 (53.8) <0.0001
 unitsb 2 (2–2) 2 (1.5–2.0) 2.0 (2.0–3.75) 0.2441
FFP      
 units (total) 0 (0–0) 0 (0–0) <0.0001
n (%) 3 (3.2) 10 (19.2) <0.0001
 unitsb 5 (5–8) 10 (10–13) 0.0097
  1. FC fibrinogen concentrate, FFP fresh frozen plasma, ISS injury severity score, IU international units, PCC prothrombin complex concentrate, RBC red blood cells. aANOVA (Kruskal Wallis) P value for all four groups; bMedian (interquartile range) in patients who received that particular product
  2. Data presented as median (interquartile range), number (%)